Indivior Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $210.0M | $7.0M | $-126.0M | $-44.0M |
| Depreciation & Amortization | $10.0M | $16.0M | $15.0M | $16.0M |
| Depreciation | $10.0M | $12.0M | $7.0M | $7.0M |
| Amortization | — | — | — | — |
| Stock-Based Compensation | $26.0M | $24.0M | $21.0M | $16.0M |
| Net Cash from Operating Activities | $-27.0M | $36.0M | $-300.0M | $-4.0M |
| Investing Activities | ||||
| Capital Expenditures | $66.0M | $29.0M | $8.0M | $5.0M |
| Business Acquisitions | $0 | $0 | $129.0M | $0 |
| Net Cash from Investing Activities | $-66.0M | $69.0M | $-95.0M | $-222.0M |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | $11.0M | $173.0M | $33.0M | $90.0M |
| Net Cash from Financing Activities | $-30.0M | $-102.0M | $-64.0M | $-101.0M |
| Net Change in Cash | — | — | — | — |
| Free Cash Flow | $-93.0M | $7.0M | $-308.0M | $-9.0M |